Actualités Celgene Corporation - CELG | Actions NASDAQ

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company...

Amgen Completes Acquisition Of Otezla® (apremilast)

Amgen Completes Acquisition Of Otezla® (apremilast) Differentiated Therapy Strengthens Amgen's Long-Standing...

Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristo...

Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE:...

CELGENE ERHÄLT DIE ZULASSUNGSEMPFEHLUNG DES CHMP FÜR LENALIDOMID (REVLIMID®) IN KOMBINATION MIT RITUXIMAB ZUR BEHANDLUNG V...

Die Kombination aus Lenalidomid (REVLIMID®) und Rituximab (R2) hat das Potenzial, eine chemotherapiefreie Behandlungsoption für rezidivierte oder...

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500 PR Newswire NEW YORK, Nov. 19, 2019 NEW YORK, Nov. 19, 2019...

Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation...

Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult...

REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules that...

FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...

REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients Approval of...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Celgene to Present New & Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annua...

Nearly 70 abstracts, including more than 20 oral presentations highlight diverse portfolio of innovative treatment modalities, including...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Celgene Corporation (CELG)

Votre Hub pour des idées et discussions en direct en temps réel

CELG Actualités

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

Amgen Completes Acquisition Of Otezla® (apremilast)

Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristo...

CELGENE ERHÄLT DIE ZULASSUNGSEMPFEHLUNG DES CHMP FÜR LENALIDOMID (REVLIMID®) IN KOMBINATION MIT RITUXIMAB ZUR BEHANDLUNG V...

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small...

FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...

Statement of Changes in Beneficial Ownership (4)

Celgene to Present New & Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annua...

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Celgene Corporation (CELG) Actualités

Celgene Corporation (CELG)

Votre Hub pour des idées et discussions en direct en temps réel

CELG Actualités

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

Amgen Completes Acquisition Of Otezla® (apremilast)

Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristo...

CELGENE ERHÄLT DIE ZULASSUNGSEMPFEHLUNG DES CHMP FÜR LENALIDOMID (REVLIMID®) IN KOMBINATION MIT RITUXIMAB ZUR BEHANDLUNG V...

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult...

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small...

FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...

Statement of Changes in Beneficial Ownership (4)

Celgene to Present New & Updated Data on Key Hematology Pipeline Therapies at American Society of Hematology (ASH) 2019 Annua...

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application